Back

Novel strategies targeting residual risk: the promise of PCSK9 inhibiting therapies.

29 August 2016 (13:25 - 13:40)
Organised by:
Congress Presentation Part of: How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation Inflammation and microcirculation ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor Erik Stroes

AmsterdamUMC location AMC, Amsterdam (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Introduction - The post ACS patient and residual risk.
Professor P. Libby (Boston, US)
Presentation thumbnail
Inflammation as potential target for therapy to target residual risk post ACS.
Doctor P. Ridker (Boston, US)
Presentation thumbnail
Beyond statins: the role of ezetimibe in targeting residual risk.
Professor C. Packard (Glasgow, GB)
Presentation thumbnail
Discussion - How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation.
Professor P. Libby (Boston, US) Professor J. Deanfield (London, GB)

Access the full session

Session thumbnail
How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation

The Event

Event poster

ESC Congress 2016

29 August 2016 13:25 CET
You may be interested in
thumbnail
Congress Presentation
Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study
1 September 2025
thumbnail
Congress Presentation
Residual risk in dyslipidaemias: from statins to PCSK9 inhibitors and beyond.
29 August 2022
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources